A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Inclusion Criteria:

- Participants must be undergoing their first cardiac allograft transplant

- Women of childbearing potential must have a negative serum pregnancy test within 48
hours prior to transplantation

- Women of childbearing potential must use two reliable forms of contraception
simultaneously. Effective contraception must be used before beginning study drug
therapy, and for 4 months following discontinuation of study drug therapy

- Participants and/or their guardians must be willing and be capable of understanding
risks and comply with the purpose of the study

Exclusion Criteria:

- Previous organ transplants

- Participants receiving multiple organs

- Participants requiring ventricular assist device (VAD) upon completion of
transplantation surgery

- Women lactating, pregnant or of childbearing potential not using, or who are
unwilling to use two reliable forms of contraception simultaneously during the study

- History of a psychological illness or condition which would interfere with the
participant's ability to understand the requirements of the study

- White blood count =<2500/mm^3, platelets =<50,000/mm^3 or hemoglobin =<6 g/dL

- HIV-1, the presence of positive HBsAg, or chronic active hepatitis C

- Active peptic ulcer disease

- Severe diarrhea or other gastrointestinal disorders which might interfere with their
ability to absorb oral medication

- Malignancies within the past 5 years, excluding skin carcinoma that have been
adequately treated

- Participants who have received within the past 30 days or require concomitant
treatment with other investigational drugs or immunosuppressive medications that are
prohibited for this study

- Inability to start microemulsion form of cyclosporine within 72 hours